Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Aug 12, 2024
Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis
Presented first-in-human data from SZN-043 Phase 1a trial at EASL
Read more at globenewswire.comNASDAQ:SRZN (12/8/2025, 3:38:11 PM)
20.6
+0.14 (+0.68%)
Find more stocks in the Stock Screener
